Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-09-08

Clinical Trial Update: A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction [Phase 2]

View source ↗

Summary

Phase 2 trial of AGN-195263 for Meibomian Gland Dysfunction has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AGN-195263

Snippet

Sponsor: Allergan | Conditions: Meibomian Gland Dysfunction | Phase 2 | Status: COMPLETED | Results posted: 2017-09-08